If your dog disappears under the bed every time a firecracker goes off — or falls apart the moment you walk out the door — a landmark moment in veterinary medicine just happened that you need to hear about.
The United States Food and Drug Administration formally approved Tessie® (tasipimidine oral solution) for the treatment of noise aversion and separation anxiety in dogs. Manufactured by Orion Corporation of Finland and exclusively marketed in the United States by Zoetis, Tessie is the first FDA-approved treatment in history to carry approval for both conditions simultaneously in a single product.
This is not a minor update to existing medication. This is a genuinely new molecule — a proprietary active substance never before used in veterinary medicine — entering the market as the answer to one of the most common, most distressing, and most undertreated problems in canine behavioural health.
Two Conditions. One Dog. A Problem That Is Far More Common Than You Think.
Noise aversion and separation anxiety are the two most frequently reported behavioural disorders in dogs. Yet for years, they were treated as separate conditions requiring separate drugs, separate diagnoses, and separate conversations with your vet.
The problem with that approach is that the two conditions are deeply connected. Research shows that as many as 40% of dogs who struggle with separation anxiety also experience intense fear of loud or sudden noises. The same underlying neurology — a hyperactive fight-or-flight response — drives both. A dog that panics when left alone is often the same dog that shakes uncontrollably during a thunderstorm.
Until Tessie, if your dog had both conditions, your vet had to manage two separate prescriptions, two separate dosing schedules, and two separate monitoring protocols. The experience for the dog — and the pet parent — was fragmented at best, and often incomplete.
What Tessie® Actually Is — And How It Works
Tasipimidine, the active ingredient in Tessie, is an alpha-2 adrenoceptor agonist. In plain terms: it works by activating specific receptors in the brain that directly reduce the dog’s heightened sympathetic nervous system activity — the biological engine of the fight-or-flight response.
Unlike older sedatives that may simply make dogs sleepy, the goal of tasipimidine is to reduce panic while still allowing dogs to remain alert and functional. This is a critical distinction. Previous generations of anxiety medication often left dogs drowsy, disoriented, and disconnected. Tessie is designed to calm the fear response without switching the dog off.
Tessie is typically administered orally one hour before the expected start of either a noise-triggering stimulus such as fireworks, or one hour before leaving the dog alone. The drug can be given up to three times in a 24-hour period with several hours between doses. It is a prescription product — veterinary oversight is required for both diagnosis and management.
One important practical note from the FDA: the product should not be given with food because it can delay the drug’s absorption. Wait at least one hour after feeding before dosing.
The Science Behind the Approval
The FDA’s approval was not handed over lightly. Tasipimidine is an α-2 adrenoceptor agonist which acts by activating specific receptors in the brain to reduce heightened sympathetic nervous system activity, also known as fight-or-flight responses.
The agency evaluated two separate clinical studies — one enrolling 160 dogs with noise aversion and another following 224 dogs with separation anxiety across eight weeks — both conducted in real home environments against real-life triggers. This is significant. These were not controlled laboratory conditions. These were dogs in their actual homes, with their actual families, facing the actual sounds and situations that triggered their distress.
The results were clear enough to earn formal approval.
Niclas Lindstedt, Executive Vice President of Orion Animal Health, said: “This approval adds to Orion Animal Health’s portfolio of veterinary medicines developed to address clearly identified clinical needs. Our long-standing approach to innovation is centered on applying scientific expertise to create treatment options that support veterinary decision-making and animal welfare.”
Christopher Pachel, DVM, DACVB, a board-certified veterinary behaviourist based in Portland, Oregon, described his response simply: he loves having an FDA-approved drug that is approved for both conditions for a couple of different reasons — because it addresses a genuine gap, and because it gives vets a clean, evidenced tool to reach for when behaviour modification alone is not enough.
What Dogs With These Conditions Actually Experience
For those who have not lived with a dog suffering from noise aversion or separation anxiety, it is easy to underestimate the severity. This is not mild discomfort. This is genuine psychological distress — and it is visible.
Dogs with noise aversion are sensitive to and fearful of loud noises such as fireworks, street and traffic noises, and gunshots. Dogs with separation anxiety are fearful of or have underlying anxiety about being left alone. Dogs experiencing these types of distress may hide, vocalize by whining, barking or howling, pant, shake or tremble, or they may vomit, urinate and defecate.
For pet parents, watching this unfold is genuinely distressing. For the dogs, it is a recurring experience of acute fear — one that, without treatment, typically worsens over time as the anxiety becomes more deeply conditioned.
Why This Matters So Much for India
India does not yet have Tessie on the market. The approval is currently US-specific, with Zoetis holding exclusive marketing rights in the United States. There is no confirmed timeline for availability in India or other markets.
But the story matters enormously for Indian pet parents for two reasons.
First, the awareness it creates. Millions of dogs across India experience severe noise aversion — every Diwali, every wedding season, every New Year’s Eve. The condition is widespread, it is serious, and it has historically been undertreated because pet parents did not know there was a medical solution available, and because the options that existed were limited and imperfect. Tessie’s approval confirms what veterinary behaviourists have been saying for years: this is a medical condition, not a personality quirk, and it deserves medical attention.
Second, Tessie signals what is coming. The global veterinary pharmaceutical market is evolving rapidly, and approvals of this kind tend to reach major markets — including India — within two to four years of the initial US clearance, particularly when distributed by a company with Zoetis’s global reach. Indian vets and pet parents should be aware of what is available and what is on its way.
In the meantime, if your dog has significant noise aversion or separation anxiety, the message from this approval is clear: talk to your veterinarian. Evidence-based solutions exist. This approval is proof of that.
What You Can Do Right Now — For Your Anxious Dog in India
While Tessie is not yet available in India, there are evidence-based steps you can take today in conversation with your veterinarian.
Speak to a veterinarian or veterinary behaviourist. Anxiety in dogs is a medical condition. It responds to treatment. Your first step is always a proper diagnosis and professional guidance — not guesswork or home remedies.
Do not wait for Diwali. Anxiety conditions worsen without intervention. If your dog shows fear responses to fireworks, thunderstorms, or being left alone, start that veterinary conversation now — not the week before the festival season.
Behaviour modification works alongside medication. Tessie, like all anxiety medications, is designed to complement — not replace — behavioural therapy. Gradual desensitisation and counter-conditioning techniques, guided by a professional, remain the gold standard for long-term management.
Document your dog’s symptoms. Before your vet appointment, note when the fear episodes occur, what triggers them, how long they last, and what behaviours your dog displays. The more specific the information, the more effectively your vet can guide you toward the right treatment approach.
Create a safe space at home. A quiet, enclosed room — away from windows, with familiar smells and a piece of your worn clothing — can help during acute episodes. This is not a cure, but it reduces the immediate stress response while longer-term treatment is established.
The Bigger Picture — Canine Mental Health Is Finally Getting Serious
The approval of Tessie is part of a larger and genuinely exciting shift in veterinary medicine. The idea that dogs have emotional lives, that they experience fear and distress in ways that are medically real and medically treatable, was not always mainstream. For decades, anxious dogs were managed with general sedatives, dismissed as “difficult,” or simply endured by their families.
That is changing. The investment in understanding canine behaviour, in developing targeted pharmacological tools, and in building the clinical infrastructure to support veterinary behaviourists is accelerating globally. Tessie is the clearest single example of where that investment leads — a purpose-built, rigorously tested molecule for a specific behavioural indication, approved by the world’s most respected regulatory agency.
For every dog hiding under a bed during Diwali, and for every pet parent watching helplessly and not knowing what to do — this is the beginning of better answers.
Pets News Network (PNN) is India’s first dedicated OTT and news platform for the pet industry. Published: July 2026. This article does not constitute veterinary medical advice. Do not attempt to source, import, or administer any prescription veterinary medication without a valid prescription and direct guidance from a licensed veterinarian.
